---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-25-000024"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:43:55.081037+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences appoints Dietmar Berger to board replacing Merdad Parsey

## Summary
- Merdad Parsey resigned from Arcus board effective upon Gilead's new director designee; he left Gilead.
- Dietmar Berger, Gilead's CMO since Jan 2025, appointed as Class II director to fill vacancy.
- Dr. Berger will not receive compensation for board service; Arcus will enter standard indemnification agreement.
- Changes made pursuant to Amended and Restated Investor Rights Agreement between Arcus and Gilead.

## SEC filing metadata
- accession: 0001724521-25-000024
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000024/0001724521-25-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000024/rcus-20250206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-25-000024
- JSON: https://secwatch.observer/filing/0001724521-25-000024.json
- Plain text: https://secwatch.observer/filing/0001724521-25-000024.txt

## Key facts
- Executive change
  Dietmar Berger was appointed as Class II Director at Arcus Biosciences, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: On February 6, 2025, the Board appointed Dietmar Berger M.D., Ph.D., as a Class II director to fill the vacancy left by Dr. Parsey's resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000024/0001724521-25-000024-index.htm
- Executive change
  Merdad Parsey resigned as Director at Arcus Biosciences, Inc..
  - Action: resigned
  - Role: Director
  source text: On February 6, 2025, in connection with his departure from Gilead Sciences, Inc. (“Gilead”), Merdad Parsey, M.D., Ph.D., resigned as a member of Arcus Biosciences, Inc.’s (“Arcus”) Board of Directors (the “Board”), effective upon the appointment of Gilead’s new director designee pursuant to the Amended and Restated Investor Rights Agreement dated January 29, 2024 by and between Arcus and Gilead.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000024/0001724521-25-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.